These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 23348820)

  • 1. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis.
    Poms AD; Turner M; Farber HW; Meltzer LA; McGoon MD
    Chest; 2013 Jul; 144(1):169-176. PubMed ID: 23348820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.
    Barst RJ; Chung L; Zamanian RT; Turner M; McGoon MD
    Chest; 2013 Jul; 144(1):160-168. PubMed ID: 23429998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).
    Benza RL; Miller DP; Gomberg-Maitland M; Frantz RP; Foreman AJ; Coffey CS; Frost A; Barst RJ; Badesch DB; Elliott CG; Liou TG; McGoon MD
    Circulation; 2010 Jul; 122(2):164-72. PubMed ID: 20585012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-Year outcomes of patients enrolled in the REVEAL Registry.
    Farber HW; Miller DP; Poms AD; Badesch DB; Frost AE; Muros-Le Rouzic E; Romero AJ; Benton WW; Elliott CG; McGoon MD; Benza RL
    Chest; 2015 Oct; 148(4):1043-54. PubMed ID: 26066077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management.
    Barst RJ; McGoon MD; Elliott CG; Foreman AJ; Miller DP; Ivy DD
    Circulation; 2012 Jan; 125(1):113-22. PubMed ID: 22086881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).
    Preston IR; Roberts KE; Miller DP; Sen GP; Selej M; Benton WW; Hill NS; Farber HW
    Circulation; 2015 Dec; 132(25):2403-11. PubMed ID: 26510696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry.
    Frost AE; Farber HW; Barst RJ; Miller DP; Elliott CG; McGoon MD
    Chest; 2013 Jan; 143(1):185-195. PubMed ID: 22661451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management.
    Shapiro S; Traiger GL; Turner M; McGoon MD; Wason P; Barst RJ
    Chest; 2012 Feb; 141(2):363-373. PubMed ID: 21757572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis.
    Frost AE; Badesch DB; Miller DP; Benza RL; Meltzer LA; McGoon MD
    Chest; 2013 Nov; 144(5):1521-1529. PubMed ID: 23907471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.
    Farber HW; Miller DP; Meltzer LA; McGoon MD
    J Heart Lung Transplant; 2013 Nov; 32(11):1114-22. PubMed ID: 24035189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Portopulmonary hypertension: a report from the US-based REVEAL Registry.
    Krowka MJ; Miller DP; Barst RJ; Taichman D; Dweik RA; Badesch DB; McGoon MD
    Chest; 2012 Apr; 141(4):906-915. PubMed ID: 21778257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic BP and heart rate as prognostic indicators in pulmonary arterial hypertension.
    Bersohn MM; Turner MP; Traiger GL; Frost AE; Shapiro S
    Chest; 2013 Sep; 144(3):959-965. PubMed ID: 23598723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
    Vizza CD; Hoeper MM; Huscher D; Pittrow D; Benjamin N; Olsson KM; Ghofrani HA; Held M; Klose H; Lange T; Rosenkranz S; Dumitrescu D; Badagliacca R; Claussen M; Halank M; Vonk-Noordegraaf A; Skowasch D; Ewert R; Gibbs JSR; Delcroix M; Skride A; Coghlan G; Ulrich S; Opitz C; Kaemmerer H; Distler O; Grünig E
    Chest; 2021 Aug; 160(2):678-689. PubMed ID: 33581097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry.
    Chung L; Farber HW; Benza R; Miller DP; Parsons L; Hassoun PM; McGoon M; Nicolls MR; Zamanian RT
    Chest; 2014 Dec; 146(6):1494-1504. PubMed ID: 24992469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries.
    Frost AE; Badesch DB; Barst RJ; Benza RL; Elliott CG; Farber HW; Krichman A; Liou TG; Raskob GE; Wason P; Feldkircher K; Turner M; McGoon MD
    Chest; 2011 Jan; 139(1):128-37. PubMed ID: 20558556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) pulmonary hypertension prediction model in a unique population and utility in the prediction of long-term survival.
    Cogswell R; Kobashigawa E; McGlothlin D; Shaw R; De Marco T
    J Heart Lung Transplant; 2012 Nov; 31(11):1165-70. PubMed ID: 23062726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry.
    Burger CD; Long PK; Shah MR; McGoon MD; Miller DP; Romero AJ; Benton WW; Safford RE
    Chest; 2014 Nov; 146(5):1263-1273. PubMed ID: 24901386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.
    Benza RL; Miller DP; Barst RJ; Badesch DB; Frost AE; McGoon MD
    Chest; 2012 Aug; 142(2):448-456. PubMed ID: 22281797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry.
    Brown LM; Chen H; Halpern S; Taichman D; McGoon MD; Farber HW; Frost AE; Liou TG; Turner M; Feldkircher K; Miller DP; Elliott CG
    Chest; 2011 Jul; 140(1):19-26. PubMed ID: 21393391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.